Publicaciones en las que colabora con Patricia Pozo Rosich (19)

2024

  1. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review

    Frontiers in Neurology , Vol. 15

  2. Headaches and facial pain attributed to SARS-CoV-2 infection and vaccination: a systematic review

    European Journal of Neurology, Vol. 31, Núm. 6

  3. Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

    Journal of Headache and Pain, Vol. 25, Núm. 1

  4. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  5. Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment

    Medicina Clinica, Vol. 163, Núm. 4, pp. 208.e1-208.e10

  6. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

  7. Reply to the letter: Headaches during/after SARS-CoV-2 infection/vaccination can be primary and secondary as well as acute and chronic, by Finsterer J and Mehri S

    European Journal of Neurology

2022

  1. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

2021

  1. 1st Post-European Headache Federation Meeting: A review of the latest developments presented at the 2020 European Headache Federation Congress

    Revista de Neurologia

  2. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  3. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas

    Scientific Reports, Vol. 11, Núm. 1

  4. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

    Journal of Headache and Pain, Vol. 22, Núm. 1

  5. Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and the Spanish Society of Neurosurgery

    Neurologia, Vol. 36, Núm. 1, pp. 61-79

  6. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2020

  1. Estimating the savings associated with a migraine-free life: results from the Spanish Atlas

    European Journal of Neurology, Vol. 27, Núm. 12, pp. 2616-2624

  2. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108

  3. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

2019

  1. Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice

    Neurologia, Vol. 34, Núm. 6, pp. 408-417

2018

  1. Impacto y situación de la Migraña en España: Atlas 2018

    Editorial Universidad de Sevilla